Andrew McConaghie

A bid to fast track the PD-1xVEGF candidate in non-small cell lung cancer has failed – and raises the stakes for partner Akeso's upcoming ASCO presentation.

The UK biotech has developed a platform which it believes can overcome shortcomings in previous technologies and challenge CD3-based T cell engagers.

The Danish company has achieved the best ever obesity launch thanks to consumer enthusiasm for a cut price oral Wegovy

The company aims to create a new modified DNA therapy class which avoids the downsides of traditional gene therapy, gene editing or RNA therapeutics.

The first Phase II study of a novel treatment acquired with Cardior failed to improve heart function in hard-to-treat patients, but further trials are ongoing.

The Scrip Awards 2026 are now open for entries, with a debut for the AI in Drug Discovery Award, plus an interview with one of last year's winners.

This year's American Society of Gene and Cell Therapy congress saw a surge of companies presenting early results on circular RNA platforms – but major challenges remain for the novel technology.

Three deaths on board a cruise ship have caused concern, but the Andes hantavirus strain remains a low pandemic risk and vaccine firm Moderna will not accelerate development of its preclinical candidate.

Acquisition of the biotech and its non-viral DNA delivery technology adds to a string of bets across next-generation approaches in gene-based therapies.

Switzerland-based company is pioneering use of copper-based radiopharmaceuticals, and has plans to enter Phase I this year.